Table 2.
Progression-free survival analysis of each predictor variable (Univariate).
| Predictor Variables | Median Survival (m) (95% CI) | 1-Year PFS (%) | 3-Year PFS (%) | p Value |
|---|---|---|---|---|
| Age (years) | 0.692 | |||
| ≤61 (n = 56) | 9.5 (5.5–13.5) | 44.1 | 25.3 | |
| >61 (n = 53) | 10.2 (6.4–14.0) | 43.5 | 16.0 | |
| Gender | 0.024 | |||
| Male (n = 63) | 12.9 (3.3–22.5) | 52.4 | 29.6 | |
| Female (n = 46) | 8.3 (5.8–10.8) | 32.3 | 11.5 | |
| Body mass index | 0.001 | |||
| <18.5 (n = 8) | 3.2 (2.5–4.0) | 0 | 0 | |
| 18.5–27 (n = 83) | 11.4 (6.5–16.3) | 46.7 | 22.3 | |
| >27 (n = 18) | 11.3 (7.5–15.1) | 50.0 | 26.7 | |
| Sarcopenia | 0.005 | |||
| Yes (n = 25) | 4.6 (3.3–6.0) | 16.8 | 4.6 | |
| No (n = 84) | 13.1 (6.3–19.9) | 51.6 | 13.1 | |
| Lymphocyte count | 0.008 | |||
| ≤858 (n = 29) | 6.2 (3.3–9.2) | 20.7 | 10.3 | |
| >858 (n = 80) | 12.9 (4.5–21.3) | 52.5 | 25.6 | |
| Neutrophil/lymphocyte ratio | 0.122 | |||
| ≤2.14 (n = 32) | 14.3 (6.4–22.2) | 58.6 | 27.4 | |
| >2.14 (n = 61) | 7.2 (3.8–10.5) | 34.4 | 16.8 | |
| Monocyte/lymphocyte ratio | 0.106 | |||
| ≤0.19 (n = 33) | 12.0 (3.2–20.9) | 53.1 | 34.0 | |
| >0.19 (n = 60) | 7.4 (5.1–9.7) | 35.6 | 13.7 | |
| Platelet/lymphocyte ratio | 0.009 | |||
| ≤270 (n = 75) | 13.8 (7.1–20.7) | 53.4 | 25.9 | |
| >270 (n = 34) | 6.2 (2.5–9.9) | 23.5 | 11.8 | |
| ECOG | 0.017 | |||
| 0 (n = 24) | 24.6 (5.2–44.0) | 62.5 | 30.8 | |
| 1/2 (n = 69) | 9.0 (57.3–12.6) | 42.8 | 20.9 | |
| 3 (n = 16) | 3.0 (51.8–4.2) | 16.7 | 8.4 | |
| Albumin (g/dL) | 0.343 | |||
| ≤3.5 (n = 44) | 5.6 (52.2–8.9) | 36.7 | 19.9 | |
| >3.5 (n = 65) | 11.7 (58.2–15.3) | 48.7 | 22.8 | |
| Direct to Sunitinib | 0.223 | |||
| No (n = 49) | 8.3 (56.1–10.5) | 33.4 | 13.4 | |
| Yes (n = 60) | 12.9 (55.1–20.7) | 51.6 | 27.4 | |
| Sunitinib dose (mg) | 0.029 | |||
| 25 (n = 17) | 6.5 (1.3–11.7) | 35.3 | N/A | |
| 37.5 (n = 79) | 10.2 (6.3–14.0) | 43.5 | 20.3 | |
| 50 (n = 13) | 19.1 (-) | 56.4 | 47.0 | |
| Primary site | 0.658 | |||
| Stomach (n = 39) | 11.3 (8.3–14.3) | 50.2 | 23.2 | |
| Small bowel (n = 53) | 10.2 (4.7–15.6) | 44.7 | 21.6 | |
| Colorectum (n = 8) | 14.3 (0.1–28.7) | 62.5 | 23.4 | |
| Others (n = 9) | 8.3 (6.9–9.6) | 33.3 | 11.1 | |
| Metastatic site | 0.005 | |||
| Non-liver (n = 39) | 22.6 (14.4–30.8) | 70.6 | 34.1 | |
| Liver (n = 70) | 7.0 (3.4–10.5) | 29.1 | 14.5 | |
| Genetic status (Secondary mutation) | 0.232 | |||
| Exon 13 (n = 14) | 23.3 (9.0–37.5) | 69.6 | 31.3 | |
| Exon 17 (n = 10) | 8.3 (0.4–16.2) | 50.0 | 0.0 | |
| Hypertension | 0.001 | |||
| No (n = 81) | 8.3 (5.3–11.2) | 35.7 | 12.4 | |
| Yes (n = 28) | 28.3 (17.9–38.7) | 67.1 | 44.7 | |
| Hand–foot syndrome | <0.0001 | |||
| No (n = 66) | 5.6 (2.4–8.7) | 29.5 | 13.1 | |
| Yes (n = 43) | 19.7 (12.6–26.7) | 65.0 | 33.5 | |
| Diarrhea | 0.021 | |||
| No (n = 67) | 7.4 (3.5–11.4) | 33.4 | 15.1 | |
| Yes (n = 42) | 19.7 (7.3–32.0) | 59.5 | 30.6 | |
| Fatigue | 0.141 | |||
| No (n = 72) | 11.4 (7.0–15.9) | 47.4 | 25.5 | |
| Yes (n = 37) | 9.4 (2.5–16.3) | 36.9 | 14.2 | |
| Anemia | 0.548 | |||
| No (n = 39) | 11.4 (8.3–14.5) | 46.2 | 17.9 | |
| Yes (n = 70) | 9.0 (5.1–12.9) | 42.7 | 23.8 | |
| Thrombocytopenia | 0.268 | |||
| No (n = 82) | 9.4 (7.1–11.7) | 41.0 | 19.2 | |
| Yes (n = 27) | 13.8 (6.3–21.4) | 52.8 | 28.8 | |
| Leukopenia | 0.726 | |||
| No (n = 80) | 9.0 (5.7–12.3) | 42.7 | 22.1 | |
| Yes (n = 29) | 11.6 (7.2–16.0) | 46.7 | 19.4 | |
| Anorexia | 0.162 | |||
| No (n = 83) | 11.3 (7.0–15.6) | 47.1 | 24.4 | |
| Yes (n = 26) | 9.4 (3.7–15.1) | 32.8 | 12.3 | |
| Edema | 0.053 | |||
| No (n = 90) | 10.2 (6.2–14.1) | 47.6 | 24.5 | |
| Yes (n = 19) | 4.6 (3.2–6.1) | 24.6 | 6.1 | |
| Hepatic toxicity | 0.559 | |||
| No (n = 94) | 9.5 (6.2–12.8) | 42.3 | 21.3 | |
| Yes (n = 18) | 16.3 (0.1–35.1) | 53.3 | 22.9 | |
| Hypothyroid | 0.152 | |||
| No (n = 104) | 9.5 (6.7–12.3) | 42.0 | 19.3 | |
| Yes (n = 5) | 39.2 (17.3–61.1) | 80.0 | 60.0 |